NASDAQ:HALO - Halozyme Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $17.37 +0.17 (+0.99 %) (As of 07/18/2018 08:00 AM ET)Previous Close$17.20Today's Range$17.09 - $17.4552-Week Range$11.41 - $21.48Volume605,400 shsAverage Volume653,610 shsMarket Capitalization$2.48 billionP/E Ratio38.60Dividend YieldN/ABeta1.9 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company's pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and cholangiocarcinoma and gall bladder cancer. In addition, the company develops PEGylated adenosine deaminase 2, an immune checkpoint inhibitor that targets adenosine. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; and Alexion Pharma Holding. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. Receive HALO News and Ratings via Email Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:HALO CUSIP40637H10 Webwww.halozyme.com Phone858-794-8889 Debt Debt-to-Equity Ratio0.39 Current Ratio4.06 Quick Ratio4.03 Price-To-Earnings Trailing P/E Ratio38.60 Forward P/E Ratio-18.88 P/E GrowthN/A Sales & Book Value Annual Sales$316.61 million Price / Sales7.90 Cash Flow$0.4599 per share Price / Cash37.77 Book Value$1.46 per share Price / Book11.90 Profitability EPS (Most Recent Fiscal Year)$0.45 Net Income$62.97 million Net Margins21.52% Return on Equity45.31% Return on Assets15.93% Miscellaneous Employees255 Outstanding Shares143,970,000Market Cap$2,476.21 Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions What is Halozyme Therapeutics' stock symbol? Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO." How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.22) by $0.03. The biopharmaceutical company earned $30.90 million during the quarter, compared to the consensus estimate of $31.84 million. Halozyme Therapeutics had a return on equity of 45.31% and a net margin of 21.52%. The business's quarterly revenue was up 4.4% on a year-over-year basis. During the same period last year, the business earned ($0.26) EPS. View Halozyme Therapeutics' Earnings History. When is Halozyme Therapeutics' next earnings date? Halozyme Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Halozyme Therapeutics. What price target have analysts set for HALO? 8 Wall Street analysts have issued 1 year price objectives for Halozyme Therapeutics' stock. Their predictions range from $7.00 to $29.00. On average, they expect Halozyme Therapeutics' stock price to reach $19.75 in the next year. This suggests a possible upside of 13.7% from the stock's current price. View Analyst Ratings for Halozyme Therapeutics. What is the consensus analysts' recommendation for Halozyme Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 2 sell ratings, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." Who are some of Halozyme Therapeutics' key competitors? Some companies that are related to Halozyme Therapeutics include Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), argenx (ARGX), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Acceleron Pharma (XLRN) and Repligen (RGEN). Who are Halozyme Therapeutics' key executives? Halozyme Therapeutics' management team includes the folowing people: Dr. Helen I. Torley, Pres, CEO & Director (Age 55)Ms. Laurie D. Stelzer, Sr. VP & CFO (Age 50)Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 61)Mr. Mark J. Gergen, Former Chief Operating Officer (Age 55)Dr. Michael J. LaBarre Ph.D., Chief Scientific Officer and VP (Age 54) Has Halozyme Therapeutics been receiving favorable news coverage? News headlines about HALO stock have trended positive on Wednesday, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Halozyme Therapeutics earned a coverage optimism score of 0.36 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 46.64 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. Who are Halozyme Therapeutics' major shareholders? Halozyme Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.32%) and Xact Kapitalforvaltning AB (0.02%). View Institutional Ownership Trends for Halozyme Therapeutics. Which institutional investors are selling Halozyme Therapeutics stock? HALO stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC. View Insider Buying and Selling for Halozyme Therapeutics. Which institutional investors are buying Halozyme Therapeutics stock? HALO stock was bought by a variety of institutional investors in the last quarter, including Xact Kapitalforvaltning AB. View Insider Buying and Selling for Halozyme Therapeutics. How do I buy shares of Halozyme Therapeutics? Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Halozyme Therapeutics' stock price today? One share of HALO stock can currently be purchased for approximately $17.37. How big of a company is Halozyme Therapeutics? Halozyme Therapeutics has a market capitalization of $2.48 billion and generates $316.61 million in revenue each year. The biopharmaceutical company earns $62.97 million in net income (profit) each year or $0.45 on an earnings per share basis. Halozyme Therapeutics employs 255 workers across the globe. How can I contact Halozyme Therapeutics? Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected] MarketBeat Community Rating for Halozyme Therapeutics (NASDAQ HALO)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 295 (Vote Outperform)Underperform Votes: 246 (Vote Underperform)Total Votes: 541MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe HALO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: What does RSI mean?